13F Holdings
中文EN

VKTX Viking Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1607678 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-164.2%
TTM EPS YoY-155.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-96.4%
ROA-73.1%
ROIC (approx.)-195.7%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets39.8%
Debt / equity0.00x
Current ratio7.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-19.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$0$0$0
R&D expense$344.95M$101.64M$63.81M$54.23M$44.98M
SG&A expense$48.39M$49.28M$37.02M$16.12M$10.70M
Operating income-$393.34M-$150.92M-$100.83M-$70.36M-$55.68M
Pretax income-$359.64M-$109.96M-$85.89M——
Income tax$1,000$1,000$1,000$1,000$2,000
Net income-$359.64M-$109.96M-$85.89M-$68.87M-$54.99M
EPS (basic)-3.19-1.01-0.91-0.90-0.71
EPS (diluted)-3.19-1.01-0.91-0.90-0.71
Weighted avg. shares (diluted)112.67M109.04M94.35M76.83M77.20M
Balance sheet
Cash & equivalents$165.81M$26.68M$55.52M$36.63M$26.37M
Short-term investments$539.93M$875.94M$306.56M$118.85M$175.73M
Current assets$715.60M$907.22M$367.23M$167.04M$210.53M
Total assets$715.73M$908.32M$368.49M$168.53M$210.66M
Current liabilities$76.67M$27.41M$19.14M$21.95M$8.78M
Total liabilities$76.67M$28.04M$20.07M$23.21M$8.78M
Shareholders' equity$639.06M$880.28M$348.42M$145.32M$201.88M
Shares outstanding114.79M111.57M100.11M78.26M78.25M
Cash flow statement
Operating cash flow-$278.69M-$87.79M-$73.38M-$48.40M-$47.59M
Investing cash flow$341.39M-$553.37M-$179.09M$54.75M$37.96M
Financing cash flow$76.44M$612.46M$271.38M$4.16M$6.88M
Stock-based compensation$40.82M$29.71M$16.75M$8.67M$6.10M
Share buybacks———$6.79M—

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.